Kaçan, Turgut Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Babacan, Nalan Akgün Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Yücel, Birsen Cumhuriyet Üniversitesi - Tıp Fakültesi - Radyasyon Onkolojisi Anabilim Dalı, Turkey , Kılıçkap, Saadettin Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Akkaş, Ebru Atasever Sivas Numune Hastanesi - Radyasyon Onkolojisi Kliniği, Turkey , Şeker, Mehmet Metin Cumhuriyet Üniversitesi - Tıp Fakültesi - Tıbbi Onkoloji Bilim Dalı, Turkey , Eren, Mehmet Fuat Cumhuriyet Üniversitesi - Tıp Fakültesi - Radyasyon Onkolojisi Anabilim Dalı, Turkey , Eren, Ayfer Ay Cumhuriyet Üniversitesi - Tıp Fakültesi - Radyasyon Onkolojisi Anabilim Dalı, Turkey

The factors effecting survival of stage IV non-small cell lung cancer patients

33317

Aim. The purpose of this study is to examine the prognostic factors effecting the survival of stage IV non-small cell lung cancer patients. Method. Demographic, clinical and histopathologic data from 2006 to 2011 were collected from non-small cell lung cancer patients who were treated in our clinic. With the permission of the patients who didn’t attend to routine follow-ups, their names were searched in identification interrogation system in order to use their identity information in survival analysis. In order to analyze frequency distributions, Mann-Whitney U test and Kaplan-Meier survival analysis were used. Results. A hundred (88%) male, 13 (12%) female of total 113 patients data were analyzed. The mean age was 62 (37-82). 90 (80%) of the patients were smokers, family history existed in 27 (24%) of the patients, 40 (35%) of patients were with comorbidities. According to the histopathological aspect; 24 (21%) patients were epidermoid, 30 (27%) adenocarsinoma, 3 (2%) neuroendocrine, 56 (50%) patients had unspecified non-small cell lung carcinoma. The most common Eastern Cooperative Oncology Group Perfromance Status was ECOG 1. Frequent sites of metastasis: 40 (35%) brain, 36 (32%) bone, 24 (21%) liver, 20 (18%) opposite lung. Chemotherapy was given to 83 (73%) patient whereas supportive therapy was given to 30 (27%) of the patients. Pain-killers were used in 84 (74%) patients, palliative radiotherapy was apllied to 69 (61%). Median follow-up was 8 months (1-47), median survival was 8 months. One-year overall survival was 35 Eastern Cooperative Oncology Group Perfromance Status (p 0.001), and chemotherapy (p 0.001), and usage of cisplatin (p 0.001) and docetaxel (p=0.043) during the treatment, increased levels of lactic dehydrogenase (p=0.007) were the prognostic factors effecting the survival. Chemotherapy (p 0.001) and high lactic dehydrogenase levels (p=0.004) were the independent prognostic factors. Conclusion. In stage IV non-small cell lung cancer the most important prognostic factors effecting the survival are chemotherapy and elevated lactic dehydrogenase levels.

332

Stage IV non , small cell lung cancer , survival , prognosis

Cumhuriyet Medical Journal

338